
|Articles|December 22, 2010
Novartis completes Alcon acquisition.
Novartis has agreed to purchase the remaining 23% of their share in Alcon for $168 per share.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Revisiting an overlooked solution for high myopia
2
FLORetina 2025: Industry advances front and center at FLORetina Congress
3
The accessibility barriers still hindering ophthalmology
4
FLORetina Congress celebrates 10 years with joint World Retinopathy of Prematurity meeting
5















































